Signaling Pathway
| Catalog No | Chemical Name | CAS Number | Purity | Chemical Structure |
|---|---|---|---|---|
| 20518 | BMS-986141 | 1478711-48-6 | 98% Min. |  |
| BMS-986141 is an Orally-Active Small-Molecule Antagonist of the Platelet Protease-Act | ||||
| 20519 | BMS-986120 | 1478712-37-6 | 98% Min. |  |
| BMS-986120 is a potent and selective oral antagonist of protease-activated receptor-4 | ||||
| 20618 | Pirtobrutinib | 2101700-15-4 | 98% Min. |  |
| 24004 | T-1095 | 209746-59-8 | ≧96.0% |  |
| T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs). | ||||
| 20635 | ERAS-801 ( JGK-068S ) | 2490431-16-6 | ≧98.0% |  |
| ERAS-801 ( JGK-068S ) is a potent EGFR inhibitor. | ||||
| 24008 | RNK-05047 | 2503036-46-0 | ≧98.0% |  |
| RNK-05047 is a PROTAC degrader of BRD4 which displays significant tumor growth inhibi | ||||
| 24009 | Asengeprast (FT011) | 1001288-58-9 | ≧98.0% |  |
| Asengeprast (FT011) is an anti-fibrotic agent thatreduces mRNA expression of collagen | ||||
| 24010 | Zasocitinib | 2272904-53-5 | ≧98.0% |  |
| Zasocitinib is under development for the treatment of moderate to severe plaque psori | ||||
| 24011 | Zongertinib | 2728667-27-2 | ≧98.0% |  |
| Zongertinib [BI 1810631] is a human epidermal growth factor receptor 2 (HER2) inhibit | ||||
| 24012 | Zunsemetinib | 1640282-42-3 | ≧98.0% |  |
| Zunsemetinib is an investigational oral mitogen-activated protein kinase-activated pr | ||||
| 24013 | Ziftomenib ( KO-539 ) | 2134675-36-6 | ≧98.0% | _2134675-36-6.png) |
| Ziftomenib is an oral, potent, and selective small molecule inhibitor that targets th | ||||
| 24014 | Zelasudil | 2365193-22-0 | ≧98.0% |  |
| Zelasudil is a potent, highly selective and orally-active inhibitor that targets Rho- | ||||